心脏移植和持久的机械循环支持对于特定的不太常见的心肌病
Ana Roussoulières1, Marta Farrero2, Finn Gustafsson3
1Department of Cardiology, Pulmonary Vascular Diseases, Heart Failure and Heart Transplantation Clinic, Univertsité Libre de Bruxelles, Hôpital Universitaire de Bruxelles, Hôpital Erasme, Brussels, Belgium.
CJC open
|June 30, 2025
概括
在非典型心肌病中,高级心力衰竭 (AHF) 管理需要仔细考虑系统性疾病的影响. 本综述详细介绍了特殊的AHF疗法和治疗后护理,用于诸如多变性心肌病和心脏粉症等疾病.
科学领域:
- 心脏病学 心脏病学
- 先进的心力衰竭管理管理
- 心肌病心脏病变的疾病.
背景情况:
- 进展性心力衰竭 (HF) 的临床特征需要先进心力衰竭 (AHF) 治疗,与缺血性或扩张性类型相比,在非典型心肌病症中定义不佳.
- 与某些心肌病相关的系统性疾病显著影响心脏外参与,影响AHF治疗选择.
- 了解这些细微差别对于优化治疗策略至关重要.
研究的目的:
- 审查患有特定原因特异性心肌病的患者慢性心力衰竭的临床特征和治疗方法.
- 在这些复杂的患者群体中评估高级心力衰竭治疗的作用和选择标准.
- 讨论治疗后管理方面的考虑.
主要方法:
- 文献综述侧重于因果特异性心肌病变,包括多变性心肌病变,心脏沙尔科毒症,心脏粉症和心律失常性右室心肌病变.
- 分析当前先进的心力衰竭疗法,如心脏移植和机械循环支持.
- 评估影响治疗决策和治疗结果的因素.
主要成果:
- 非典型心肌病在定义HF进展和候选AHF疗法时存在独特的挑战.
- 心脏外表现和系统性疾病严重程度是选择适当的AHF干预措施的关键决定因素.
- 对于高伤性心肌病,心脏沙尔科毒性,心脏粉症和心律失常性右室心肌病有特殊考虑.
结论:
- 在特定心肌病症中确定AHF治疗的临床特征是必不可少的.
- 根据心脏外参与和系统性疾病来定制AHF治疗对于成功的结果至关重要.
- 对于接受AHF治疗的这些复杂心肌病患者,需要全面的管理策略.
相关概念视频
01:29Cardiomyopathy V: Interprofessional Care
40
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
40
01:30Cardiomyopathy II: Dilated Cardiomyopathy
30
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30
01:22Heart Failure VI: Adjunct Therapies
38
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
38
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
64
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
64
01:30Heart Failure V: Medical Management
33
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
33